In this interim analysis, the researchers evaluated outcomes at week 4 and found that 84.7% (n=72) of the digital health group vs 33.3% (n=24) of the usual care group achieved the blood pressure target. They found that the digital health users had a greater reduction in systolic blood pressure than those who received usual care (-23.1 mm Hg vs -13.7 mm Hg). The digital health offering group also experienced a greater reduction in diastolic blood pressure compared with the usual care group (-9.4 mm Hg vs -5.4 mm Hg) as well as greater LDL changes (-18.1 mg/dL vs 0.7 mg/dL). 

The study also evaluated the value of data and insights from patient health behaviors at home. The participants in the digital health group had more discussions about lifestyle changes and received more adherence counseling and education. 


Continue Reading

“Endocrinologists should care about this study since persons with diabetes have high cardiovascular risk and controlling risk factors such as blood pressure and LDL have a powerful effect on reducing the chance of stroke or heart attack. In addition, better blood glucose control has the benefits of reducing the chances of diabetic complications,” Dr Osterberg told Endocrinology Advisor.

Digital health interventions can improve clinical outcomes by engaging patients in their own care and supporting positive health behaviors at home, he noted. This cannot only help with medication adherence but also in promoting physical activity. Additionally, it may help providers better understand the reasons for uncontrolled symptoms (medication nonadherence vs pharmacological nonresponse).  

“The digital health offering in our study combined higher patient engagement and improved provider decision-making to achieve improved control of blood pressure and lipids in patients with uncontrolled diabetes and hypertension,” said Dr Osterberg.

Reference

  1. Osterberg L, Virdi N, Kim Y, et al. First Clinical Evaluation of a Digital Health Offering to Optimize Treatment in Patients With Uncontrolled Hypertension and Type 2 Diabetes. Presented at: ACC 65th Scientific Sessions; April 2-4, 2016; Chicago, IL.